We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Helix Technologies, Inc. (“HLIX” or the “Company”) (OTC: HLIX) in connection with the proposed merger of the Company with Medical Outcomes Research Analytics, LLC (“Medical Outcomes”) in an all-stock transaction.  Pursuant to the terms of the merger agreement, HLIX stockholders will receive 0.02731 shares of a newly formed company, Forian Inc.  At close of the transaction, Medical Outcomes and HLIX will become wholly owned subsidiaries of Forian Inc., with Medical Outcomes members owning 72% of the combined company, and HLIX shareholders owning the remaining 28%.

WeissLaw is investigating whether HLIX’s board acted in the best interest of HLIX’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, whether the deal’s equity split is fair to HLIX shareholders, and whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]